1. Home
  2. Approved trials
  3. » فارسی

The effect of zinc on the treatment and clinical course of patients with SARS-cov2 (COVID-19)

Protocol summary

Study aim
The effect of zinc on the treatment and clinical course of patients with SARS-cov2 (COVID-19)
Design
Clinical trial with control group, with parallel, randomized groups, phase 2-3 on 80 patients. The Random Sample of Cases menu of spss software was used for randomization.
Settings and conduct
At Amin Hospital in Isfahan, 80 patients with COVID-19 were selected and the demographic and clinical information of the subjects included, including age, sex, initial diagnosis (cause of hospitalization), underlying disease, WBC count, ESR and CRP and LDH levels, CT scan Lung and RT PCR will be recorded for all patients prior to hospitalization. The diagnostic criterion for COVID-19 in patients to enter the study is pulmonary involvement in CT scan of the lung with RT PCR test.
Participants/Inclusion and exclusion criteria
Inclusion: 18 years of age or older Diagnosis of COVID-19 by RT PCR and CT scan of the lungs Blood oxygen levels are between 90 and 93 percent Breathing rate between 20 and 24 per minute Heart rate between 100 and 130 beats per minute Exclusion: Intubation (mechanical ventilation) Blood oxygen level below 90% Breathing rate equal to 30 or more per minute Allergic reaction to drugs Shortness of breath caused by cardiogenic pulmonary edema Pregnancy and lactation History of oxygen therapy at home Patients with end stage, lung, malignant, G6PD deficiency, diabetic ketoacidosis, cardiac arrhythmia.
Intervention groups
The control group included 40 patients with COVID-19 who were given two hydroxychloroquine sulfate tablets of 200 mg every 12 hours on the first day and then 200 mg every 12 hours. For the intervention group (40 people), in addition to the above, zinc tablets with a dose of 220 mg twice daily will be administered orally during the patient's hospital stay.
Main outcome variables
Clinical response; Mortality; hospital stay

General information

Reason for update
Acronym
IRCT registration information
IRCT registration number: IRCT20180425039414N2
Registration date: 2020-05-13, 1399/02/24
Registration timing: registered_while_recruiting

Last update: 2020-05-13, 1399/02/24
Update count: 0
Registration date
2020-05-13, 1399/02/24
Registrant information
Name
Atousa Hakamifard
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 31 3668 5555
Email address
a.hakamifard@med.mui.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2020-04-20, 1399/02/01
Expected recruitment end date
2020-05-21, 1399/03/01
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
The effect of zinc on the treatment and clinical course of patients with SARS-cov2 (COVID-19)
Public title
The effect of zinc on the treatment and clinical course of patients with SARS-cov2 (COVID-19)
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
18 years of age or older Diagnosis of COVID-19 by RT PCR and CT scan of the lungs Blood oxygen levels are between 90 and 93 percent Breathing rate between 20 and 24 per minute Heart rate between 100 and 130 beats per minute
Exclusion criteria:
Intubation(mechanical ventilation) Blood oxygen level below 90% Breathing rate equal to 30 or more per minute Allergic reaction to drugs Shortness of breath caused by cardiogenic pulmonary edema Pregnancy and lactation History of oxygen therapy at home Patients with end stage, lung, malignant, G6PD deficiency, diabetic ketoacidosis, cardiac arrhythmia
Age
From 18 years old
Gender
Both
Phase
2-3
Groups that have been masked
No information
Sample size
Target sample size: 80
Randomization (investigator's opinion)
Randomized
Randomization description
80 patients with covid19, hospitalized in Amin Hospital in Isfahan, who have a case file in the hospital registration system, are randomly assigned to two groups of 40 people using spss computer software and the intervention is randomly assigned.
Blinding (investigator's opinion)
Not blinded
Blinding description
Placebo
Not used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of Isfahan University of Medical Sciences
Street address
Isfahan University of Medical Sciences, Soffeh Ave
City
Isfahan
Province
Isfehan
Postal code
7346181746
Approval date
2020-04-03, 1399/01/15
Ethics committee reference number
IR.MUI.MED.REC.1399.074

Health conditions studied

1

Description of health condition studied
SARS-cov2(COVID-19)
ICD-10 code
U07.1
ICD-10 code description
COVID-19, virus identified

Primary outcomes

1

Description
Clinical response
Timepoint
During hospitalization
Method of measurement
Cessation of fever, improvement of shortness of breath, reduction of cough, blood oxygenation (SaO2) and hemodynamic parameters

2

Description
Mortality
Timepoint
During hospitalization
Method of measurement
Count the number of dead patients

3

Description
Hospital stay
Timepoint
During hospitalization
Method of measurement
Count the number of hospital days to improve clinical symptoms

Secondary outcomes

empty

Intervention groups

1

Description
Intervention group: Includes 40 patients with COVID-19 which for 5 days, who are given two 200 mg hydroxychloroquine sulfate tablets every 12 hours on the first day and then 200 mg every 12 hours. In addition to the above, zinc tablets with a dose of 220 mg twice a day orally during the patient's hospitalization will be prescribed.
Category
Treatment - Drugs

2

Description
Control group: Includes 40 patients with COVID-19 which for 5 days, who are given two 200 mg hydroxychloroquine sulfate tablets every 12 hours on the first day and then 200 mg every 12 hours.
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Amin Hospital
Full name of responsible person
Atousa Hakamifard
Street address
Shohadas' Square
City
Isfahan
Province
Isfehan
Postal code
8174675731
Phone
+98 31 3668 5555
Email
a.hakamifard@med.mui.ac.ir

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Esfahan University of Medical Sciences
Full name of responsible person
Ziba Farajzadegan
Street address
Research Vice Chancellor of Isfahan University of Medical Sciences, Faculty of Medicine, Hezar Jarib St.
City
Isfahan
Province
Isfehan
Postal code
8174673461
Phone
+98 31 3668 0042
Email
a.hakamifard@med.mui.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Esfahan University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Esfahan University of Medical Sciences
Full name of responsible person
Atousa Hakamifard
Position
Assistant professor
Latest degree
Specialist
Other areas of specialty/work
Infectious diseases
Street address
Alzahra hospital, Soffeh Ave
City
Isfahan
Province
Isfehan
Postal code
8174755685
Phone
+98 31 3668 5555
Fax
Email
a.hakamifard@med.mui.ac.ir

Person responsible for scientific inquiries

Contact
Name of organization / entity
Esfahan University of Medical Sciences
Full name of responsible person
Atousa Hakamifard
Position
Assistant professor
Latest degree
Specialist
Other areas of specialty/work
Infectious diseases
Street address
Alzahra hospital, Soffeh Ave
City
Isfahan
Province
Isfehan
Postal code
8174785664
Phone
+98 31 3668 5555
Fax
Email
a.hakamifard@med.mui.ac.ir

Person responsible for updating data

Contact
Name of organization / entity
Esfahan University of Medical Sciences
Full name of responsible person
Atousa Hakamifard
Position
Assistant professor
Latest degree
Specialist
Other areas of specialty/work
Infectious diseases
Street address
Alzahra hospital, Soffeh Ave
City
Isfahan
Province
Isfehan
Postal code
8174756662
Phone
+98 31 3668 5555
Fax
Email
a.hakamifard@med.mui.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Yes - There is a plan to make this available
Statistical Analysis Plan
Yes - There is a plan to make this available
Informed Consent Form
Yes - There is a plan to make this available
Clinical Study Report
Yes - There is a plan to make this available
Analytic Code
Yes - There is a plan to make this available
Data Dictionary
Yes - There is a plan to make this available
Title and more details about the data/document
All information can be shared two months after the results are published.
When the data will become available and for how long
Two months after the results are published.
To whom data/document is available
Doctors, nurses, and infectious disease specialists
Under which criteria data/document could be used
To evaluate other complementary therapies and compare their effects with existing COVID-19 therapy
From where data/document is obtainable
Send email to a.hakamifard@med.mui.ac.ir
What processes are involved for a request to access data/document
Two months after the publication of the results, send your email to a.hakamifard@med.mui.ac.ir and write your request clearly. In this case, and finally within a month after receiving the email and the above will be answered.
Comments
Loading...